PrimeVax is a clinical stage biotech and the world’s first company developing a cancer immunotherapy using dengue virus (DV). Our non-genetically modified DV strain is well-tolerated and includes 20+ years of human safety data and has the ability to address many cancer types. Our pipeline includes other DV and cell-based investigational therapies.
DV has novel MOAs: DV induces a systemic immune response, upregulates cancer killing cytokines, and DV supernatant proteins can directly kill tumors without the need for receptor cells.
Our pre-clinical models show a strong safety profile and promising early efficacy. We are IND-enabled, with clinical strategy blessed by the FDA. We are currently raising $3-8M to advance Phase 1 studies in PD-1 failed late stage Melanoma.